Cargando…

Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease

BACKGROUND: Inflammatory bowel disease (IBD) is often managed with anti‐tumour necrosis factor‐α therapy (anti‐TNFα), but treatment efficacy is compromised by high annual rates of loss of response (13%‐21% per patient‐year). AIMS: To assess whether the incidence of loss of response decreases with lo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schultheiss, Johannes P. D., Mahmoud, Remi, Louwers, Jonas M., van der Kaaij, Michiel T., van Hellemondt, Boris P., van Boeckel, Petra G., Mahmmod, Nofel, Jharap, Bindia, Fidder, Herma H., Oldenburg, Bas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Duration of Response to Anti‐tnf Agents in IBD
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292495/ https://www.ncbi.nlm.nih.gov/pubmed/34559428 http://dx.doi.org/10.1111/apt.16605

Ejemplares similares

Limited long‐term treatment persistence of first anti‐TNF therapy in 538 patients with inflammatory bowel diseases: a 20‐year real‐world study
por: Blesl, Andreas, et al.
Publicado: (2021)

Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti‐TNF therapy in a tuberculosis endemic region
por: Ye, Lingna, et al.
Publicado: (2020)

The effect of treatment delay on time‐to‐recovery in the presence of unobserved heterogeneity
por: van Geloven, Nan, et al.
Publicado: (2020)

Understanding anti‐TNF treatment failure: does serum triiodothyronine‐to‐thyroxine (T3/T4) ratio predict therapeutic outcome to anti‐TNF therapies in biologic‐naïve patients with active luminal Crohn's disease?
por: Lin, Simeng, et al.
Publicado: (2022)

Adherence to Adalimumab Was Not Improved by a Reminder-Based Intervention with an Electronic Needle Container
por: Schultheiss, Johannes P. D., et al.
Publicado: (2020)

A comparison of the beta‐geometric model with landmarking for dynamic prediction of time to pregnancy
por: van Eekelen, Rik, et al.
Publicado: (2019)

Mucosal IL13RA2 expression predicts nonresponse to anti‐TNF therapy in Crohn's disease
por: Verstockt, Bram, et al.
Publicado: (2019)

Sleep duration and mortality – Does weekend sleep matter?
por: Åkerstedt, Torbjörn, et al.
Publicado: (2018)

Immunosuppressive drugs : developments in anti-rejection therapy
Publicado: (1994)

Antibioterapia en porcino : enfoque práctico
por: Fraile, Lorenzo
Publicado: (2016)

Directed Search of Anti-inflammatory Agents Among (3H-Quinazoline-4-ylidene)hydrazides of N-protected Amino acids and their Heterocyclization Products
por: Martynenko, Yulya, et al.
Publicado: (2020)

The Impact of Inflammatory Profile on Selenium Levels in Hemodialysis Patients
por: Bacci, Marcelo R., et al.
Publicado: (2020)

Anti-inflammatory Property of AMP-activated Protein Kinase
por: Noor, Humaira B., et al.
Publicado: (2020)

Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy
por: Colombel, J.‐F., et al.
Publicado: (2016)

Anti-tumor necrosis factor therapy in patients with inflammatory bowel disease; comorbidity, not patient age, is a predictor of severe adverse events
por: Asscher, Vera E. R., et al.
Publicado: (2020)

Opportunistic Knocks: A Gardener with Ulcerative Colitis and New Pulmonary Nodules
por: Canakis, Andrew, et al.
Publicado: (2023)

Drug survival of anti‐TNF agents compared with vedolizumab as a second‐line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers
por: Rundquist, Sara, et al.
Publicado: (2020)

MECA : mejora de la calidad de los antimicrobianos : recomendaciones SEQ /
Publicado: (2006)

Dictionary of antibiotics and related substances
Publicado: (1988)

Pharmaceutical microbiology
Publicado: (1998)

Terapéutica antimicrobiana /
por: Biro, Carlos E., 1932-
Publicado: (1980)

Infectología clínica /
Publicado: (2008)

IBD LIVE Case Series–Case 2: Previous Cancer in a Patient with Crohn's Disease: Is It Appropriate to Use Biologics and Immunosuppressants for IBD Treatment?
por: Le, Peter N., et al.
Publicado: (2015)

A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease
por: Piester, Travis, et al.
Publicado: (2018)

Mendelian Disease Associations Reveal Novel Insights into Inflammatory Bowel Disease
por: Han, Lichy, et al.
Publicado: (2018)

The Association Between Sustained Poor Quality of Life and Future Opioid Use in Inflammatory Bowel Disease
por: Anderson, Alyce, et al.
Publicado: (2018)

Incidence, prevalence and clinical outcome of anaemia in inflammatory bowel disease: a population‐based cohort study
por: Eriksson, Carl, et al.
Publicado: (2018)

Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis
por: Mahadevan, Uma, et al.
Publicado: (2018)

Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience
por: Lichtenstein, Gary R, et al.
Publicado: (2018)

What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn’s Disease Treated With Vedolizumab?
por: Card, Timothy, et al.
Publicado: (2018)

Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases
por: Ghosh, Subrata, et al.
Publicado: (2017)

Communication Between Physicians and Patients with Ulcerative Colitis: Reflections and Insights from a Qualitative Study of In-Office Patient–Physician Visits
por: Rubin, David T., et al.
Publicado: (2017)

Risk of dementia in patients with inflammatory bowel disease: a Danish population‐based study
por: Rønnow Sand, Jakob, et al.
Publicado: (2022)

Giving anti-VEGF injections: an update from Burundi
por: Niyonzima, Jean Claude
Publicado: (2023)

Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases
por: Volkers, Adriaan, et al.
Publicado: (2022)

Implications for sequencing of biologic therapy and choice of second anti‐TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti‐TNF therapy (IMSAT) therapeutic drug monitoring study
por: Chanchlani, Neil, et al.
Publicado: (2022)

Management of Recurrent Clostridioides Infection: A Difficile Problem in Inflammatory Bowel Disease Patients
por: Lam, Angela Y., et al.
Publicado: (2020)

Going Viral: Management of IBD in the Era of the COVID-19 Pandemic
por: Gutin, Liat S., et al.
Publicado: (2020)

Lower Extremity Palpable Purpura in a Patient with Quiescent Inflammatory Bowel Disease
por: Darlington, Kimberly, et al.
Publicado: (2023)

Thioguanine is Effective as Maintenance Therapy for Inflammatory Bowel Disease: A Prospective Multicentre Registry Study
por: Simsek, Melek, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k0qmdjdbc40qsv688djqs4rf76